These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32569513)

  • 1. Utility of
    Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
    AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
    [No Abstract]   [Full Text] [Related]  

  • 2. The Clinical Utility of
    Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
    Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer.
    Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA
    Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
    Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
    AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
    Kim EH; Siegel BA; Teoh EJ; Andriole GL;
    Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL.
    Garza D; Kandathil A; Xi Y; Subramaniam RM
    Nucl Med Commun; 2021 Aug; 42(8):907-913. PubMed ID: 33741863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
    Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
    AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
    [No Abstract]   [Full Text] [Related]  

  • 10. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evidence of
    Friedrich NA; Gu L; Waller J; De Hoedt AM; Klaassen Z; Freedland SJ
    Prostate; 2024 Oct; 84(14):1336-1343. PubMed ID: 39031050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMA-targeted Radiotracers versus
    Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
    Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
    J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
    J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on
    Abiodun-Ojo OA; Jani AB; Akintayo AA; Akin-Akintayo OO; Odewole OA; Tade FI; Joshi SS; Master VA; Fielder B; Halkar RK; Zhang C; Goyal S; Goodman MM; Schuster DM
    J Nucl Med; 2021 Aug; 62(8):1089-1096. PubMed ID: 33517323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
    Teyateeti A; Khan B; Teyateeti A; Chen B; Bridhikitti J; Pan T; Peng W; Macapinlac HA; Lu Y
    Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
    England JR; Paluch J; Ballas LK; Jadvar H
    Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hormonal therapy on
    Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
    Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bicentric retrospective analysis of clinical utility of
    Salavati A; Gencturk M; Koksel Y; Schik AN; Carroll PR; Feng FY; Rowe SP; Lawhn-Heath C; Hope TA; Froelich JW
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4463-4471. PubMed ID: 34091713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
    Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
    J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.